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ABSTRACT 
 
AMIE RODGERS: Modeling Adverse Liver Effects of Drugs using kNN QSAR method 
(Under the direction of Ivan Rusyn) 
 
 
Adverse drug reactions (ADRs) continue to be a major cause of drug withdrawals both in 
development and post-marketing. Quantitative Structure Activity Relationship (QSAR) 
models have been used to predict human ADRs in the heart. While liver ADRs are a 
major concern for drug safety, there are currently no in silico models for predicting 
human liver ADRs. The FDA has assembled a database of human liver ADR data on 490 
approved drugs. In this study, we construct a QSAR model capable of performing binary 
classification (active/inactive) for liver ADRs based on chemical structure using the k-
nearest neighbor (kNN) method and rigorous external model validation protocols. Models 
with high sensitivity (>73%) and specificity (>94%) for external test sets were built. 
Three databases were screened using our models and the predictions were analyzed. We 
conclude that QSAR modeling of liver ADRs may be useful in screening pre-clinical 
drug candidates for potential human hepatotoxicity. 
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CHAPTER I 
 
Literature Review 
 
Human adverse drug reactions (ADRs) cost upwards of $3.6 billion each year and 
constitute one of the top ten causes of death in the United States (Fontanarosa et al. 2004). 
Drug safety is a serious concern for pharmaceutical companies, regulators and the general 
public and novel approaches continue to be sought to facilitate the development of safe and 
efficacious medicines (Watkins et al. 2008). In order to accelerate the drug approval 
process, the FDA has reduced the time for review of most drugs from 27 months in 1993 to 
14 months in 2001; however, drug withdrawal rates more than doubled (from 1.56% to 
5.35%) in the same period of time (Fontanarosa et al. 2004). Despite rigorous animal 
testing and human screening in clinical trials, serious ADRs are still frequent either in late-
stage clinical trials or post-marketing of the drug, after significant investment has already 
been made. For example, troglitazone was brought to market as an anti-diabetic drug that 
worked as a PPAR α and PPARγ agonist. Troglitazone was subsequently withdrawn from 
the market after cases of liver failure and death were reported.  
Because drug ADRs are relatively uncommon, it is difficult to detect potentially 
toxic drugs in clinical testing. Several strategies for reducing cases of ADRs after the 
commercial release of new pharmaceuticals have been suggested, such as reducing direct to 
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consumer advertising, recommending new drugs to be considered as second-line treatments 
when existing and equally effective drugs are already on the market, and better 
dissemination of ADR reports (Lasser et al. 2002). ADR reporting is an involved process 
whereby a doctor makes a report to the FDA about a patient reaction to a drug, with the 
FDA following up on each report. ADRs are widely underreported, and an effort to 
emphasize the importance of reporting ADRs is needed. Dissemination of ADR data has 
also been a problem in the past, however, current projects such as the Adverse Effects 
Reporting System [http://www.fda.gov/cder/aers/default.htm] have helped to make this 
data available to the public.  
Current approaches for identification of the drug’s potential to be hepatotoxic are 
not without limitations. Pre-clinical drug safety studies which are performed in multiple 
animal species detect approximately half of compounds exhibiting hepatotoxicity in 
humans (Olson et al. 2000); likewise, in vitro human hepatocyte testing detects only 50-
60% of drugs that can cause severe liver injury, including some not detected on animal 
testing (Olson et al. 2000; Xu et al. 2008).  Thus, no currently available preclinical tests 
detect all compounds with a potential for serious human hepatotoxicity with combined high 
sensitivity and specificity (Abboud and Kaplowitz 2007; Olson et al. 2000). 
In silico screening and prioritization of compounds has been widely used for many 
years in the pharmaceutical industry to screen candidate compounds for efficacy, 
metabolite formation and “general toxicity” (Tang 2007). In silico models can also be used 
to predict toxicity based on chemical structure. QSAR modeling takes the form of a variety 
of statistical modeling techniques which range from linear techniques to sophisticated 
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variable selection non-linear machine learning algorithms. Molecular descriptors utilized 
by these methods range from 2D topological descriptors to 3D field-based descriptors. In 
general, in silico models predictive for toxicological endpoints fall into two categories, rule 
based and statistical methods. Rule based methods have been popular among toxicologists 
due to the transparent nature of correlation of particular chemical moieties with toxicicity, 
so called toxicophores. Use of toxicophores for prediction of toxicity can become 
problematic, as toxicity may be attenuated by steric or electric environment surrounding the 
toxicophore. Moreover, existence of a toxicophore is a binary classification, which may not 
be true for all compounds containing a particular toxicophore.  Either of these 
circumstances could cause false prediction. Statistical methods correlate chemical structure, 
given in terms of molecular descriptors, to a biological endpoint. A wide variety of classes 
of molecular descriptors are utilized in the creation of QSAR models including geometric, 
electronic, polar surface area and topological. Nonlinear QSAR methods such as artificial 
neural networks and kNN have been utilized to handle the nonlinear properties of these 
datasets (Devillers 1996; Zheng and Tropsha 2000b). 
The promise for organ- and mechanism-specific toxicity screening using QSAR has 
been recently demonstrated by successful prediction of the human ether-a-go-go-related 
gene (hERG) receptor binding-related ADRs in the heart (Ekins et al. 2002; Roche et al. 
2002). However, while the development of predictive QSAR models may be a promising 
approach for in silico screening for ADRs, the computational methods which are available 
now suffer from scarcity of clinical data on a large number of drugs that may cause toxicity 
in humans. Because of this scarcity of clinical data, current in silico models for liver 
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toxicity generally focus on interaction of molecules with enzymes, and often cover only a 
small number of compounds. Korhonen et al created a 3D-QSAR model which predicts the 
inhibition potency of a small group of structurally diverse compounds on CYP2B6 
(Korhonen et al. 2007). Jensen et al used k nearest neighbor methodology to predict the 
inhibition potency of compounds on CYP2D6 and CYP3A4 (Jensen et al. 2007). Lewis et 
al also created QSAR models of drug affinity for CYP2B family enzymes (Lewis et al. 
2006). Sakurai et al created a model to predict the inhibitory potency of compounds on the 
bile salt export pump (BSEP) (Sakurai et al. 2007). Lessigiarska et al created many models 
predictive for in vitro human liver cell toxicity and rat liver cell toxicity, though none of 
their models predicted for in vivo human liver toxicity (Lessigiarska et al. 2006).  
Elevated levels of liver enzymes detected in blood samples are frequently regarded 
by clinicians as signs of liver damage and, if other pathological states can be excluded, are 
attributed to drug-induced toxicity (Jaeschke et al. 2002). Liver enzyme tests are well 
accepted as non-invasive and universal measurement for liver integrity and function in 
humans, and thus are frequently used as a biomarker for drug-induced liver damage in 
subjects receiving various therapeutic agents (Ozer et al. 2008).  The US FDA has 
compiled a Human Liver Adverse Effects Database (HLAED) using Coding Symbols for a 
Thesaurus of Adverse Reaction Terms (COSTART) to identify reports in the FDA’s 
Spontaneous Reporting System database associated with liver toxicity endpoints (Matthews 
et al. 2004). The HLAED contains information on about 500 compounds with physician-
reported cases of drug treatment-associated elevations in activity of one or more of five 
liver enzymes: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate 
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aminotransferase (AST), lactate dehydrogenase (LDH), and gamma-glutamyl 
transpeptidase (GGT). A composite “liver toxicity” endpoint is also provided based on the 
number of active reports over all endpoints. The FDA has created models using the 
HLAED, however, results of their modeling efforts have not been published, and the 
models they developed have not been used for regulatory decisions. 
Thus, in this work we aimed to develop a QSAR model predictive for a broad range 
of compounds and biological mechanisms of human liver ADRs. Such a study may act as a 
proof of concept for the use of QSAR models that incorporate human data for human ADR 
prediction. Analysis of chemical descriptors used in modeling could yield important 
information about the chemical moieties and features responsible for liver ADRs. QSAR 
models of human liver ADR endpoints could also be used to screen large databases of 
molecules, both current and potential drugs, to flag compounds which may cause liver 
ADRs in humans. 
 
 
 
 CHAPTER II 
 
Introduction 
 
One of the most common reasons for drug withdrawal is evidence of liver ADRs. 
Liver ADRs can be caused by many mechanisms and although rare, can be fatal. It is 
difficult to predict both which individuals are susceptible to liver damage, and which drugs 
may cause liver ADRs. In vitro testing and multi-species in vivo animal testing have been 
shown to be poorly predictive of human liver ADRs (Olson et al. 2000; Xu et al. 2008). 
There are currently no pre-clinical tests which identify potential human hepatotoxicants 
with both high sensitivity and specificity (Abboud and Kaplowitz 2007; Olson et al. 2000). 
With the inadequacy of both in vitro and in vivo testing, in silico methods have been 
considered for prediction of ADRs. In silico methods, such as Quantitative Structure 
Activity Relationship (QSAR) modeling, may prove to be a valuable predictive tool for 
human ADRs. QSAR models use known activities and chemical structural properties to 
predict the activity of unknown compounds. As such, a successful QSAR model depends 
both on coverage of chemical space and available activity data. Human toxicity data is 
often difficult to procure, much of it is proprietary (particularly pre-marketing data), and 
reports of post-marketing adverse events are widely underreported. Within the available 
data, a desirable biomarker would be reasonably well correlated to toxicity, easy to procure, 
and frequently measured among the patient population. 
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Liver enzyme levels are examples of desirable biomarkers. Elevated liver enzyme 
levels are regarded as suggestive of liver damage (Jaeschke et al. 2002). Liver enzyme 
levels are easily procured through routine blood tests and are frequently used in the patient 
population to assess liver function. The US Food and Drug Administration (FDA) has 
compiled a database called the Human Liver Adverse Effects Database (HLAED) which 
contains data gleaned from the FDA’s Spontaneous Reporting System (SRS) database. 
Analysis of this database using Coding Symbols for a Thesaurus of Adverse Reaction 
Terms (COSTART) to link compounds to physician initiated reports of liver toxicity 
yielded a database consisting of several liver enzyme endpoints (Matthews et al. 2004). 
This database contains approximately 500 compounds with five liver enzyme endpoints, 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), lactate dehydrogenase (LDH), and gamma-glutamyl transpeptidase (GGT). A 
Composite liver endpoint is compiled based on the activity of the compound in the five 
liver enzyme endpoints. 
In this study, we used data from the HLAED to develop a predictive QSAR model 
of human liver ADR endpoints using k Nearest Neighbor (kNN) method. Models were 
rigorously tested and found to have high sensitivity (>73%) and specificity (>94%) for 
prediction of liver ADRs in external test sets. We show that our models may be useful for 
screening purposes by screening several large databases of compounds. Analysis of 
literature links revealed potential toxicological mechanisms that our model may predict 
particularly well for, such as oxidative stress. Mapping of commonly used descriptors onto 
compounds revealed that several active compounds contain chemical moieties that may be 
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associated with oxidative stress. The success of our models suggests that QSAR modeling 
of liver ADRs may be a useful tool for screening pre-clinical drug candidates for potential 
hepatotoxicity in humans. 
  
 
CHAPTER III 
 
Methods 
 
Data source 
Drug names, structures and activities were obtained from the HLAED 
[http://www.fda.gov/cder/Offices/OPS_IO/adverse_effect_database.htm]. Active (i.e., 
hepatotoxic in humans) and inactive (i.e., non-hepatotoxic in humans) compounds in the 
database are classified based on the number of ADR reports relative to the number of 
“shipping units” (Matthews et al. 2004). For the purposes of this work, the data set was 
curated as follows. First, compounds with marginal and “NA” scores were discarded for 
each endpoint. Second, we selected the three endpoints with the largest number of “active” 
compounds for modeling: ALT, AST and composite liver toxicity index. Third, because 
each liver toxicity endpoint the database contained approximately 10% active and 90% 
inactive compounds, chemical similarity searching was applied using MACCS (Molecular 
ACCess System) structures and Tanimoto coefficient similarity searching to select inactive 
compounds that were most structurally similar to active compounds. In this step 
structurally dissimilar inactive compounds were removed to achieve a more balanced 
dataset with active/inactive ratio of approximately 40/60 for each endpoint. Following the 
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filtering detailed above, of the 490 compounds in the HLAED, up to 210 were used for 
each endpoint.  
MolConnZ Chemical Descriptors 
The MolConnZ software (eduSoft LC, Ashland, VA) affords the computation of a 
wide range of topological indices of molecular structure. These indices include, but are not 
limited to, the following descriptors: simple and valence path, cluster, path/cluster and 
chain molecular connectivity indices, kappa molecular shape indices, topological and 
electrotopological state indices, differential connectivity indices, graph’s radius and 
diameter, Wiener and Platt indices, Shannon and Bonchev-Trinajstić information indices, 
counts of 12 different vertices, counts of paths and edges between different kinds of 
vertices (Hall LH. et al. 1991; Kier LB 1987; Kier LB and Hall LH. 1991; Kier 1987). 
Overall, MolConnZ (eduSoft LC) produces over 400 different descriptors. Those with zero 
value or zero variance were removed. The remaining descriptors were range-scaled since 
the absolute scales for MolConnZ (eduSoft LC) descriptors can differ by orders of 
magnitude. Accordingly, our use of range scaling avoided giving descriptors with 
significantly higher ranges a disproportional weight upon distance calculations in 
multidimensional MolConnZ (eduSoft LC) descriptor space.  
Dragon Chemical Descriptors 
Molecular descriptors were computed using Dragon (v.5.4, Talete SRL, Milano, 
Italy) software. Only simple structural descriptors, directly derived from the SMILES 
notation for each studied compound were calculated; the three-dimensional (3D) 
descriptors were not computed. The typology of the included descriptors is as follows: 0D-
constitutional (atom and group counts); 1D-functional g
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fragments; 2D-topological descriptors; 2D-walk and path counts; 2D-autocorrelations; 2D-
connectivity indices; 2D-information indices; 2D-topological charge indices; 2D-
Eigenvalue-based indices; 2D-topological descriptors; 2D-edge adjacency indices; 2D-
Burden eigen values; molecular properties. 
 
QSAR Modeling 
Selection of Test and Training Sets: The dataset was subdivided into multiple 
training/test set pairs using the Sphere Exclusion program (Golbraikh et al. 2003). The 
number of compounds included in the test set was gradually increased to obtain the largest 
possible test set for which accurate predictions could be obtained from models developed 
for the corresponding smallest possible training set. 
The procedure implemented in this study starts with the calculation of the distance 
matrix D between points that represent compounds in the descriptor space. Let Dmin and 
Dmax be the minimum and maximum elements of D, respectively. N probe sphere radii are 
defined by the following formulas. Rmin = R1 = Dmin, Rmax = RN = Dmax/4, Ri = R1 + 
(i-1)*(RN-R1)/(N-1), where i = 2, ..., N-1. Each probe sphere radius corresponds to one 
division into the training and the test set. A sphere-exclusion algorithm used in this study 
consisted of the following steps. (i) Randomly select a compound. (ii) Include it in the 
training set. (iii) Construct a probe sphere around this compound. (iv) Select compounds 
from this sphere and include them alternately into the test and the training sets. (v) Exclude 
all compounds from within this sphere from further consideration. (vi) If no more 
compounds are left, stop. Otherwise let m be the number of probe spheres constructed and 
n be the number of remaining compounds. Let dij (i=1,...,m; j=1,...,n) be 
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the distances between the remaining compounds and the probe sphere centers. Select a 
compound corresponding to the lowest dij value and go to step (ii). This algorithm 
guarantees that at least in the entire descriptor space (i) representative points of the test set 
are close to representative points of the training set (test set compounds are within the 
applicability domain defined by the training set); (ii) most of the representative points of 
the training set are close to representative points of the test set; (iii) the training set 
represents the entire modeling set (i.e. there is no subset in the modeling set which is not 
represented by a similar compound in the training set) (Golbraikh et al. 2003). As a result, 
the Sphere Exclusion algorithm can maximize the diversity of the training/test sets in the 
descriptor space used for modeling. Due to stochastic nature of the algorithm, the 
composition of training and test sets is different for different original dataset divisions.  
The statistical significance of models was characterized with the standard leave-
one-out cross-validated R2 (q2) for the training sets and the conventional R2 for the test sets. 
Models were considered acceptable if both q2 and R2 were larger than the arbitrary cutoff 
values (0.6 was used as a cutoff in this study). Models that did not meet these cutoff criteria 
were discarded. Additional details of this approach are described elsewhere (Golbraikh et 
al. 2003; Golbraikh and Tropsha 2002). 
kNN QSAR Method: The kNN QSAR method employs the kNN pattern 
recognition principle and a variable selection procedure. Initially, a subset of nvar (number 
of selected variables) descriptors is selected randomly. The model developed with this set 
of descriptors is tested by leave-one-out cross-validation, where each compound is 
eliminated from the training set and its biological activity is predicted as the average 
activity of k most similar molecules (k=1 to 5). The weighted molecular similarity was 
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characterized by the modified Euclidean distance between compounds in the nvar subspace 
of the multidimensional descriptor space. In general, the Euclidean distances in the 
descriptor space between a compound and each of its k nearest neighbors are not the same. 
Thus, the neighbor with the smaller distance from a compound was given a higher weight 
in calculating the predicted activity as follows (Eq. 1 & 2): 
)(exp
)exp(
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where di is the Euclidean distance between the compound and its k nearest neighbors; wi is 
the weight for every individual nearest neighbor; yi is the actual activity value for nearest 
neighbor i; and yˆ is the predicted activity value. A method of simulated annealing with the 
Metropolis-like acceptance criteria is used to optimize the variable selection. In summary, 
the kNN-QSAR algorithm generates both an optimum k value and an optimal nvar subset 
of descriptors, that afford a QSAR model with the highest training set model accuracy as 
estimated by the q2 value. Further details of the kNN method implementation, including the 
description of the simulated annealing procedure used for stochastic sampling of the 
descriptor space, are given in our previous publications (Ng et al. 2004; Shen et al. 2003b; 
Zheng and Tropsha 2000a). 
Applicability Domain of kNN QSAR Models: Formally, a QSAR model can 
predict the target property for any compound for which chemical descriptors can be 
calculated. However, since all the models are developed in kNN QSAR modeling by 
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interpolating activities of the nearest neighbor compounds only in the relevant training sets, 
a special applicability domain (i.e., similarity threshold) should be introduced to avoid 
making predictions for compounds that differ substantially from the training set molecules. 
This procedure resembles that for identifying chemical outliers prior to the onset of 
modeling. 
In order to measure similarity, each compound is represented by a point in the M 
dimensional descriptor space (where M is the total number of descriptors in the descriptor 
pharmacophore) with the coordinates Xi1, Xi2, ..., XiM, where Xis are the values of 
individual descriptors. The molecular similarity between any two molecules is 
characterized by the Euclidean distance between their representative points. The Euclidean 
distance di,j between two points i and j (which correspond to compounds i and j) in M-
dimensional space can be calculated as follows (Eq. 3): 
∑
=
−=
M
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jkikij XXd
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                                                       [3] 
Compounds with the smallest distance between one another are considered to have 
the highest similarity. The similarity of compounds in our training set are compiled to 
produce an applicability domain threshold, DT, calculated as follows (Eq. 4): 
σZyDT +=                                                                                   [4] 
Here, y is the mean Euclidean distance to the nearest neighbor of each compound 
within the modeling set, σ is the standard deviation of these Euclidean distances, and Z is 
an arbitrary parameter to control the significance level. Based on previous studies (Shen et 
al. 2003a), we set the default value of this parameter to 0.5, which formally places the 
boundary for which compounds will be predicted at one-half of the standard deviation 
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(assuming a Boltzmann distance distribution between k nearest neighbor compounds in the 
training set). Thus, if the distance of the external compound from at least one of its k 
nearest neighbors in the training set exceeds this threshold, the prediction is considered 
unreliable. 
Robustness of QSAR models: Y-randomization (randomization of response) is a 
widely used approach to establish the model robustness. It consists of rebuilding the 
models using randomized activities of the modeling set and subsequent assessment of the 
model statistics. It is expected that models obtained for the modeling set with randomized 
activities should have significantly lower predictivity for the external validation set than the 
models built using modeling set with real activities, or the total number of acceptable 
models based on the randomized modeling set satisfying the same cutoff criterion (q2 and 
R2>0.6) is much less than that based on real modeling set. If this condition is not satisfied, 
real models built for this modeling set are not reliable and should be discarded. This test 
was applied to all data divisions considered in this study. Correct classification rate (CCR) 
was calculated for all external test sets. The CCR is defined as: 
)//(5.0 NTNPTPCCR += where P and N are the number of active and inactive 
compounds in the dataset, TP and TN are the number of known active compounds 
predicted to be active (true positives) and the number of inactive compounds predicted to 
be inactive (true negatives), respectively.  
 
  
 
 
CHAPTER IV 
 
Results 
 
The HLAED contains 490 pharmaceutical compounds. Compounds are classified at 
each endpoint as active, marginal, inactive, or N/A. Table 1 provides a summary of raw 
data from the HLAED compared to data used for modeling. The raw data from the HLAED 
has an uneven distribution of active (19.2%) versus inactive compounds (80.7%) 
(excluding marginal and N/A compounds). In order to correct this bias we used a similarity 
search method to remove inactive compounds which were structurally dissimilar to active 
compounds, using a method previously described (Zhu et al. 2008). Briefly, we calculated 
the MACCS structural keys for all compounds using MOE software (Chemical Computing 
Group, Montreal, Canada). We used the active compound set as a probe subset and 
compared each inactive compound to the probe subset using the Tanimoto coefficient. If an 
inactive compound had a high Tanimoto coefficient (>0.7) then the inactive compound was 
deemed highly dissimilar from the active probe subset and excluded from the final dataset. 
Using this method, 205 inactive compounds were excluded from the final Composite 
dataset, leaving 114 inactive and 76 active compounds, 60% and 40% of the final database 
respectively. 175 inactive compounds were removed from the AST endpoint dataset, 
leaving 84 active and126 inactive compounds in the final dataset. The reasoning behind 
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eliminating structurally dissimilar inactives, rather than randomly removing inactive 
compounds, is that it is more difficult to differentiate between structurally similar active 
and inactive compounds. Structurally dissimilar inactive compounds are readily identified 
using a similarity search, but QSAR modeling is often used for differentiation of 
structurally similar active and inactive compounds.  
The importance of external datasets to confirm the predictive accuracy of QSAR 
models has been discussed in depth (Golbraikh and Tropsha 2002; Zhang et al. 2006). The 
external test sets were randomly selected from each modeling dataset, 37 compounds from 
the Composite dataset (19 active and 18 inactive compounds) and 42 compounds from the 
AST dataset (16 active and 26 inactive). The remaining compounds (153 for Composite 
endpoint and 168 for AST endpoint) were used for modeling, with multiple training and 
test sets generated from each. Variable selection for kNN QSAR models was used for each 
training set, and the corresponding test set was used to assess the predictive power of each 
model generated. Cutoff values for leave-one-out cross validation accuracy and accuracy of 
test set prediction were both 0.65. The accuracy of the model was defined as the average of 
the correctly predicted active ratio (sensitivity) and the correctly predicted inactive ratio 
(specificity) because the dataset was unbalanced. The total number of models passing these 
criteria for each endpoint is 1431 and 1977 for Composite and AST endpoints, respectively. 
Average q2 values were 0.83 and 0.84 for Composite endpoint models and AST endpoint 
models respectively. Average R2 values were 0.65 and 0.66 for Composite endpoint models 
and AST endpoint models respectively. Average number of compounds in training sets was 
123 and 145 for Composite endpoint models and AST endpoint models respectively. 
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Average number of compounds in test sets was 60 and 57 for Composite endpoint models 
and AST endpoint models respectively. 
Previous studies have shown that the most accurate external dataset predictions are 
achieved using a consensus approach, i.e. averaging the predictions from individual models 
(Tropsha et al. 2003). Consensus predictions for the external datasets for each endpoint 
discussed above are detailed in Tables 2a and b. The sensitivity and specificity of the 
consensus prediction were 73.7% and 94.4%, respectively for the Composite endpoint 
models. The overall predictive power was 84.1% for the Composite endpoint models. The 
sensitivity and specificity of the consensus predictions were 87.5% and 96.2%, respectively 
for the AST endpoint models. The overall predictive power was 91.9% for the AST 
endpoint models. The sensitivity and specificity of the consensus prediction were 60% and 
88.5% respectively for the ALT endpoint models. The overall predictive power was 74.2% 
for the ALT endpoint models.  
In order to ensure the accuracy of external dataset predictions, applicability 
domains of each model were calculated. The applicability domain decreases the number of 
predictions, but increases the overall reliability of the predictions by eliminating 
compounds outside of the applicability domain, generally increasing accuracy. No 
compounds in the AST, ALT or Composite models were found to be outside of the 
applicability domain. AST and Composite endpoint models displayed the highest 
sensitivity and specificity, and therefore were used for further analysis and screening. 
A y-randomization test was performed for each model wherein activities of training 
set models were randomized. The original modeling set included 1977 and 1431 models for 
AST and Composite endpoints respectively, which exceeded the q2/R2>0.65 cutoff. When 
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active/inactive designations for the compounds were randomized, the average number of 
models which exceeded q2/R2>0.65 dropped to 117 and 295 for AST and Composite 
endpoints, respectively. This marked decrease indicates that our models are statistically 
robust and may be applied to the external databases of drugs and chemicals.  
Screening of WDI Database 
First, we used the World Drug Index, a database of over 50,000 drugs currently on 
the market worldwide, to test both the coverage and predictive ability of our model. Most 
approved drugs are presumed to have little or no liver toxicity, therefore there should be a 
small number of compounds flagged as potentially hepatotoxic. Approximately 40,000 
compounds were outside the applicability domain for our model, thus precluding us from 
using them for predictions (Figure 1). Of the remaining ~10,000 compounds, 9,000 were 
predicted to be inactive, and 1,000 were predicted to be active. Because of the large number 
of compounds, it is not possible to conduct a literature search to determine if liver ADRs 
have been reported for the compounds predicted as hepatotoxic.   
Screening of Prestwick Chemical Library 
Next, we used the Prestwick chemical library, which is a database of 880 small 
molecule pharmaceuticals. The compounds are primarily marketed drugs, so it is assumed 
that they exhibit little or no liver toxicity, therefore there should be a small number of 
compounds flagged as potentially hepatotoxic. We screened the Prestwick Chemical 
Library using the Composite Endpoint model (Figure 2). Of the 878 organic compounds, 
401 were outside of the applicability domain. Of the remaining 477 compounds, 289 were 
predicted as inactive, and 242 were flagged to be potentially hepatotoxic. We selected a 
threshold of <0.3 for inactive consensus predictions, and >0.7 for active consensus 
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predictions. Of the 92 active consensus predictions <0.7, 42 were confirmed active, 26 are 
unconfirmed, and 24 are confirmed inactive.  
Screening of Biowisdom Liver Intelligence Module 
The Biowisdom Liver Intelligence Module consists of 1822 compounds which have 
been identified via text mining as being linked to several categories of liver toxicity 
phenotypes. We screened this database using models for AST and Composite endpoints. 
Using the Composite endpoint model, 1112 compounds were outside of the applicability 
domain, 400 were predicted to be inactive, and 310 were predicted to be active (Figure 3). 
Using the AST endpoint model, 1166 compounds were outside of the applicability domain, 
373 were predicted to be inactive, and 283 were predicted to be active. Using a Kruskal-
Wallis test, we were able to find Biowisdom categories which corresponded to statistically 
significantly different average literature links between predicted active and inactive 
compounds. Figures 4a and b show the average literature links for statistically significant 
Biowisdom liver endpoints for compounds predicted positive or negative by the Composite 
and AST endpoint models.  
Some drugs, such as acetaminophen, have hundreds of associated literature links 
because they are studied extensively or used as model compounds to demonstrate particular 
toxicity. Although acetaminophen can be very toxic to liver, other drugs may be as toxic 
but not mentioned in literature as often. To correct for this, we transformed the data into 
binary, each category for each compound was scored either ‘0’ (no literature links) or ‘1’ 
(has at least one literature link). When the Kruskal-Wallis test was performed again, only 
oxidative stress had significantly different proportions of compounds with at least one 
literature link, and this was only found in compounds predicted active or inactive by the 
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AST model. Interestingly, these results seem to indicate that our models may be highly 
predictive for liver injury caused by oxidative stress. This is supported by chemical 
moieties which are known to cause oxidative stress that were found to be used frequently in 
our models.  
 Screening of a Special External Test Set 
To determine whether the model can differentiate between structurally similar 
active and inactive compounds, a special external test set was explored (kindly provided by 
Dr. P. Watkins). This specialized external test set consists of five pairs of structurally 
similar compounds that were all non-hepatotoxic in preclinical studies, however one of 
each pair was found to cause hepatotoxicity in clinical studies or post-marketing. Table 3 
shows the structures of the specialized external test set pairs. We screened the specialized 
external dataset using AST and Composite endpoint models with Dragon descriptors. Both 
models gave the same predictions, summarized in Table 3. Almost half of the predictions 
were outside of the applicability domain. The remaining predictions had highly sensitivity 
(100%) but not specificity (25%).   
 CHAPTER V 
Discussion 
We have developed models predictive for AST and composite endpoints with 
high sensitivity (>70%) and specificity (>94%) using Dragon descriptors and kNN QSAR 
methods. Models developed with MolconnZ descriptors were not as sensitive or specific 
(data not shown). This may be because Dragon and MolconnZ employ several different 
categories of descriptors, Dragon descriptors represent more pharmacological endpoints 
(logP, prediction of drug like indices), and MolconnZ descriptors are mainly of structural 
origin.  
The models built for ALT were not as sensitive or specific as those built for AST 
or Composite endpoints. Though suggestive of liver damage, elevations in ALT or AST 
alone do not confirm liver damage. While ALT is known to show high sensitivity and is 
considered as moderately specific biomarker of liver damage, ALT levels have been 
known to be elevated due to other organ damage as well. AST activity is also known to 
fluctuate throughout the day and increase with exercise. These elevations in these 
biomarkers alone do not generally confirm liver damage, and it has been suggested that a 
broad range of biomarkers should be considered instead of a single biomarker (Ozer et al. 
2008). It is possible that our Composite liver endpoint model is successful because the 
data is drawn from several biomarkers, rather than a single biomarker. 
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A model predictive for human liver ADRs could be useful in early stage screening 
of pharmaceutical compounds and could potentially reduce attrition rates, as well as 
adverse health effects and costs associated with liver ADRs. We screened the World 
Drug Index and predicted approximately 1,000 compounds as potentially active. The 
poor annotation of the WDI and the large quantity of compounds predicted to be active 
made it infeasible to confirm predictions for all compounds. Still, of the many 
compounds predicted to be active within the external dataset, there are several well 
known hepatotoxicants. Isoniazid is known to cause cholestasis and hepatic necrosis 
(Tostmann et al. 2008). Isoniazid was predicted to be active by both the AST and 
Composite endpoint models. Lamotrigine is known to cause infrequent, potentially 
immune related hepatotoxicity, and was also predicted to be active by the Composite 
endpoint model. Mercaptopurine has been associated with idiosyncratic hepatitis and 
cholestatic liver injury, and was predicted to be active by both AST and Composite 
models (Gisbert et al. 2007). 
Mapping of structural descriptors back onto compounds predicted to be active 
revealed several frequently used descriptors which are associated with the metabolism 
and activation of the compounds (Figure 6). One of the most frequently used descriptors 
in our models quantifies the number of hydroxyl groups attached to an aromatic ring. The 
conversion of aromatic hydroxyl groups to form semiquinones or quinones state has been 
known exert oxidative stress on hepatocytes via superoxide formation, and to bind to 
liver microsome proteins (Bolton et al. 2000; Dybing et al. 1976). Oxidative stress, 
covalent binding of reactive metabolites to important cellular proteins, and immune 
reaction can lead to damage of hepatocytes and release of liver enzymes into the blood.  
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Our AST model predicted methyldopa to be active (increasing liver enzymes in 
blood). Methyldopa contains two aromatic hydroxyl groups which form methyl dopa 
semiquinone and methyldopa quinone. Methyldopa has been found to cause hepatitis in 
humans, presumably via protein binding and immune reaction (Zimmerman 1998). 
Immune reactions may be triggered by haptens formed by drug molecules binding to liver 
proteins, or by redox imbalance alone (Lavergne et al. 2008). Another commonly used 
descriptor quantifies aliphatic carboxylic acid groups. While the carboxylic acid moiety 
of methyldopa is not directly responsible for methyldopa’s toxicity, cleavage of the 
carboxylic acid moiety is required for the bioactivation of methyldopa to 
methyldopamine. Methyldopamine can be converted to methyldopamine semiquinone, 
which is thought to be the main toxic metabolite of methyldopa (Zhou et al. 2005). 
Two other chemical descriptors were frequently used in our models, one 
quantifies pyrimidines, while the other quantifies aromatic amines. Trimethoprim, an 
antibacterial drug, contains an aminopyrimidine moiety, which consists of a pyramidine 
and two aromatic amines. Trimethoprim was predicted by our models to be active and 
has been known to cause hepatotoxicity when administered with sulfamethoxazole or 
alone. Trimethoprim may exert toxicity by the activation of the aminopyrimidine moiety 
to an iminoquinone, which may cause oxidative stress in hepatocytes. The iminoquinone 
moiety of trimethoprim may also bind to cellular proteins, possibly explaining 
hypersensitivity and resultant liver damage found in one subject after rechallenge with 
trimethoprim (Guyton et al. 1993).  
  
CHAPTER VI 
 
Conclusions and Future Directions 
 
This study shows that it is possible to use human ADR data to create QSAR models 
with high sensitivity and specificity for external test sets. We have shown that these models 
can be used to screen large databases of drugs for potential human hepatotoxicants. We 
have succeeded in confirming the activity of compounds predicted to be active in the PCL 
database. Our screening and analysis of the Biowisdom Liver Intelligence Module infers 
that our model may be predictive for compounds which cause hepatotoxicity via an 
oxidative stress mechanism. We have demonstrated that with adequate associated 
biological data, successful model predictions based on chemical structure may link to 
particular biological mechanisms.  
QSAR models of human ADRs are important because current in vitro and in vivo 
drug testing methods are not adequate for prediction of ADRs (Olson et al. 2000; Xu et al. 
2008). Our models may be useful for pre-clinical screening of drugs to predict compounds 
which may cause liver ADRs in humans. In an early development stage, the model may 
help to narrow potential drug candidates to compounds less likely to cause liver ADRs. 
Compounds would still be subject to regulatory testing including animal testing and clinical 
testing in humans, however, our models could prioritize compounds and may reduce 
attrition rates associated with clinical and post-marketing liver ADRs.  
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This work is not without limitations. When screening the WDI database, 80% of the 
compounds screened were outside of the applicability domain. In this case, our model lacks 
coverage of adequate chemical space to make predictions for those 40,000 compounds. The 
small applicability domain is certainly a limitation of our models, but is also a benefit 
because it ensures that, as with the external dataset, the models are predicting the screening 
databases with high sensitivity and specificity. The accuracies of the AST and Composite 
endpoint models were very high for the external datasets, 93% and 84% respectively, 
which shows that the models predict well for compounds which are derived from the 
HLAED. The accuracy of the model predictions may drop when screening a database of 
drugs and drug like compounds, as these compounds may be further away from the model 
compounds in chemical space, yet still within the applicability domain.  
Spontaneous reporting of adverse drug events has several limitations, some of 
which have been addressed by the FDA during the compilation of the HLAED. There is no 
way of knowing for certain how many patients are exposed to a drug on the market, 
although the FDA has attempted to correct for this by using shipping units while 
calculating the report index featured in the HLAED. The reports available may be 
incomplete or inaccurate, and due to the voluntary nature of reporting, it can be assumed 
that adverse events are widely underreported. Different countries fall under separate 
regulatory agencies, and reporting procedures may vary from country to country, making it 
difficult to compare or compile data between nations (Hauben and Bate 2009). The 
HLAED only contains data from the United States, making it easier to compile the data, but 
potentially ignoring valuable international data. Although flawed, the HLAED does 
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provide important human ADR data, which we have shown can be used for modeling 
purposes.  
Limitations in the accuracy of predicting structurally similar compounds with 
divergent toxicities were demonstrated in our screening of the specialized external dataset. 
Our models did not correctly predict the activities of most of the compounds in the 
specialized external dataset, and this supports the fact that in some cases chemical 
mechanisms alone do not account for differing toxicities in structurally similar compounds. 
For example, ibuprofen is a commonly used analgesic drug which is sold over the counter 
and not regarded to cause hepatotoxicity. Ibufenac differs structurally from ibuprofen by a 
single methyl group, but causes hepatotoxicity in humans. It was suggested that current in 
silico methodologies may not predict human ADRs well not because of a lack of coverage 
of chemical space, but because of a lack of understanding of the complexities of human 
risk factors and disease pathways (Johnson and Rodgers 2006). Perhaps in these cases the 
differential toxicities arise from biological mechanisms such as alterations in protein 
expression, complex cellular pathway disturbances, disease pathways or other risk factors 
not taken into account by chemical descriptors.  
We have previously shown that inclusion of high throughput screening (HTS) data 
found in the PubChem database can be used to improve model predictions (Zhu et al. 2008) 
Currently, the National Center for Computational Toxicology is engaged in an ongoing 
effort to screen large numbers of compounds using up to date high throughput screening 
(HTS) methods through a program called ToxCast [http://www.epa.gov/ncct/toxcast/]. 
Future studies may utilize relevant biological HTS endpoints from the ToxCast program for 
inclusion into computational models, possibly improving results in the cases of chemically 
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similar compounds with differing hepatotoxic effects. The addition of biological 
descriptors in concert with chemical descriptors may be an important step to predicting 
human liver ADRs in silico.  
 
 
36
 
Table 1. Summary of Human Liver Adverse Events Database (HLAED) activity data 
 
Classification Originala 
Composite 
Modelingb 
Composite 
Original 
AST 
Modeling 
AST 
Activec 76 76 84 84 
Marginald 2 0 16 0 
Inactivee 319 114 301 126 
NAf 93 0 89 0 
Total 490 190 490 210 
a. Original refers to the compounds found within the HLAED 
b. Modeling refers to compounds remaining to be used for modeling after structurally 
dissimilar inactive compounds are removed (see text for more detail) 
c. Active refers to compounds which are associated with a significant number of adverse 
effect reports during five years of marketing 
d. Marginal refers to compounds which are deemed marginally active 
e. Inactive refers to compounds which are not associated with a significant number of 
adverse effect reports during five years of marketing 
f. NA refers to compounds which did not have any adverse effects reports during the steady 
state, but may have had one or more adverse effect report during their first five years of 
marketing 
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Table 2a. Prediction of external test set for Composite liver enzyme score (active/inactive) 
using kNN 
 
 Direct Consensus Prediction 
Composite Exp. Actives Exp. Inactives 
Pred. Actives 14 5 
Pred. Inactives 1 17 
Sensitivity 73.7% 
Specificity 94.4% 
Overall 
Predictive 
Power* 
84.1% 
CCR** 0.85 
*The overall predictive power is the average value of sensitivity (predictive rate of actives) 
and specificity (predictive rate of inactives). 
** CCR is the average of the sum of the ratio of true positives to positives and true 
negatives to negatives. 
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Table 2b. Prediction of external test set for an increase in AST activity (active/inactive) 
using kNN 
 
 Consensus Prediction 
AST Exp. Actives Exp. Inactives 
Pred. Actives 14 2 
Pred. Inactives 1 25 
Sensitivity 87.5% 
Specificity 96.2% 
Overall 
Predictive 
Power* 
91.85% 
CCR** 0.93 
*The overall predictive power is the average value of sensitivity (predictive rate of actives) 
and specificity (predictive rate of inactives). 
** CCR is the average of the sum of the ratio of true positives to positives and true 
negatives to negatives. 
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Figure 1: Summary of World Drug Index (WDI) database screening results. 
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Figure 2: Summary of PCL database screening results. 
 
 
24
26
96
104
185
401
42
Outside appicability domain
Inactive <0.3
Inactive >0.3
Active <0.7
Active with confirmed inactivity
Active with unconfirmed activity
Active with confirmed activity
 
 42
Figure 3: Summary of Biowisdom Liver Intelligence Module screening results. 
373
2831166
Inactive
Active
Outside Applicability 
Domain
 43
Figure 4a. Average literature links for statistically significant categories: Composite score. 
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Figure 4b. Average literature links for statistically significant categories for AST activity. 
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Figure 5. Proportion of compounds with literature links for statistically significant 
categories  
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Figure 6. Selection of compounds predicted to be active by both AST and Composite 
endpoint models. Chemical descriptors frequently used in the models were mapped back 
onto the compound structures. 
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